TARSUS PHARMACEUTICALS, INC. Retained Earnings
TARSUS PHARMACEUTICALS, INC. (TARS) had Retained Earnings of -$452.15 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$452.15M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$433.60M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$426.63M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$418.25M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$452.15M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$433.60M 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$426.63M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$418.25M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$405.67M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$385.33M 10-Q · filed 2025-05-01 |
| 2024-12-31 | -$360.21M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$337.10M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$313.68M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$280.39M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$244.66M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$202.75M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$163.61M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$132.18M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$108.76M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$95.16M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$72.65M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$66.91M 10-Q · filed 2022-05-11 |
| 2021-12-31 | -$46.67M 10-K · filed 2023-03-17 |
| 2021-09-30 | -$31.82M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$16.12M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$22.47M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$32.84M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$21.38M 10-Q · filed 2020-11-25 |
| 2019-12-31 | -$6.03M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |